在前列腺癌患者的雄激素缺乏治疗期间评估和管理心血管风险的实用指南
Aum J Solanki1, Mitchell Kamrava2, Edwin M Posadas3
1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Cancer
|March 26, 2024
概括
前列腺癌的雄激素剥夺疗法 (ADT) 增加了心血管风险. 在ADT期间优化心血管健康至关重要,需要癌症专家和初级保健专家之间的合作,以进行有效的查和风险管理.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 内部医学 内部医学
背景情况:
- 前列腺癌是全球男性的主要恶性瘤.
- 雄激素剥夺疗法 (ADT) 是前列腺癌的标准治疗方法.
- 观察性研究将ADT与心血管事件风险增加联系起来,特别是在高风险人群中.
研究的目的:
- 审查前列腺癌中的雄激素剥夺疗法 (ADT).
- 为治疗ADT的患者指导心血管查和降低风险的策略.
- 突出管理前列腺癌患者心血管疾病的重要性.
主要方法:
- 关于ADT和心血管结果的文献综述.
- 对有关ADT和心血管风险的观察数据的分析.
- 对癌症患者心血管风险管理的当前指南的综合.
主要成果:
- ADT与较高的心血管事件发生率有关.
- 患有先前存在的心血管风险因素的患者特别容易受到伤害.
- 非癌症原因,主要是心血管疾病,是前列腺癌患者的主要死亡原因.
结论:
- 在前列腺癌的ADT期间,必须优先考虑心血管健康.
- 瘤学和初级保健之间的多学科沟通是必不可少的.
- 针对这种患者群体,主动查和可修改心血管风险因素的管理至关重要.
相关概念视频
Disorders of the Male Reproductive System
404
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
404
Assessment of the Cardiovascular System I: Subjective Data
323
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
323
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


